tirzepatide and prednisone Is Mounjaro a Steroid? Understanding for Weight Management Prednisone and Mounjaro: Drug Interactions

Generation I Semaglutide GLP-1 only Peak Weight Loss 14.9% STEP 1 trial 68 weeks Receptor Coverage Single GLP-1 FDA Status Approved (Wegovy, 2021) FIRST PUBLISHED Wilding et al., NEJM 2021 Generation II Tirzepatide GLP-1 + GIP Peak Weight Loss 22.5% SURMOUNT-1 trial 72 weeks Receptor Coverage Dual GLP-1, GIP FDA Status Approved (Zepbound, 2023) First Published Jastreboff et al., NEJM 2022 Generation III Retatrutide GLP-1 + GIP + GCGR Peak Weight Loss 24.2% Phase 2 48 weeks (highest dose) Receptor Coverage Triple GLP-1, GIP, GCGR FDA Status Phase 3 (TRIUMPH program) First Published Jastreboff et al., NEJM 2023 -SELECTED LITERATURE Key Retatrutide research and clinical publications

1998;19(6):717-797 Brazeau P, Vale W, Burgus R, et al

10.4103/NRR.NRR-D-23-01508 118 ZitkaO.SkalickovaS.GumulecJ.MasarikM.AdamV.HubalekJ.et al (2012)

The STEP trial extension data showed that participants regained approximately 40 percent of lost weight within 28 weeks of stopping semaglutide